 |
 |

Treatment of PemphigusThe Need for More Evidence
Linda K. Martin, BA, BSc(Med), MBBS, MMed(ClinEpi);
Dedee F. Murrell, MA, BM BCh, FAAD, MD
Arch Dermatol. 2008;144(1):100-101.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Pemphigus vulgaris is a prototype antibody-mediated autoimmune disorder in which autoantibodies against desmosomal intraepidermal adhesion proteins lead to acantholysis and blister formation. Although our understanding of the molecular pathogenesis of pemphigus and other autoimmune bullous diseases has increased markedly in recent decades, similar progress regarding effective treatment has not been made.
There are a large number of potential interventions for pemphigus.1 The cornerstone of treatment is corticosteroids, although use of immunosuppressive agents, immunomodulatory agents, plasmapheresis, intravenous immunoglobulin, and biological agents has also been described. The efficacy and role of each of these agents has not been established.
The advent of synthetic glucocorticosteroids in the 1950s revolutionized the treatment and prognosis of pemphigus, with mortality rates improving from 90% to 10%. Unfortunately, in the ensuing 5 decades, there has been little advancement in treatment, and the . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED ARTICLE
Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris
Victoria P. Werth, David Fivenson, Amit G. Pandya, Diana Chen, M. Joyce Rico, Joerg Albrecht, and David Jacobus
Arch Dermatol. 2008;144(1):25-32.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Dapsone: Is It Useful in Pemphigus?
Journal Watch Dermatology 2008;2008:3-3.
FULL TEXT
|